Abbott Laboratories (ABT) risk factors: FY2025 10-K

1. Disruptions to Abbott’s global supply chain, which is large and complex, could negatively affect Abbott’s results of operations.
2. Abbott may acquire other businesses, license rights to technologies or products, form alliances, or dispose of or spin-off businesses, which could cause it to incur significant expenses and could negatively affect profitability.
3. Abbott depends on sophisticated information systems and maintains protected personal data, and a significant cybersecurity incident or other disruption affecting these information systems or protected data could have a material adverse effect on Abbott’s business, financial condition and results of operations.Cybersecurity
4. Abbott’s research and development efforts to develop commercially successful products and technologies and its efforts to develop and maintain new business and operating models necessary to support data-driven healthcare solutions may not succeed, either of which may cause Abbott’s revenue and profitability to decline.
5. The manufacture of many of Abbott's products is a highly exacting and complex process, and if Abbott or one of its suppliers or manufacturers encounters problems manufacturing products, Abbott’s business could suffer.
6. Abbott will incur additional indebtedness in connection with the Exact Sciences acquisition, which could adversely affect its business, including decreasing its business flexibility.new

Read these in Item 1A · See the changes

1. It is costly for Abbott to comply with numerous governmental regulations and to develop compliant products and processes, and consequences for non-compliance could have a material adverse effect on Abbott's revenues, profitability, cash flows, and financial condition.
2. Laws and regulations affecting government benefit programs could impose new obligations on Abbott, require Abbott to change its business practices, and restrict its operations, which could result in a material adverse effect on Abbott's revenues, profitability, and financial condition.
3. Changes in the healthcare regulatory environment may adversely impact the demand for and price of Abbott’s products.
4. The expiration or loss of intellectual property protection and licenses may affect Abbott’s future revenues and operating earnings.reworded
5. Significant safety concerns could arise for Abbott’s products, which could have a material adverse effect on Abbott’s revenues and financial condition.

Read these in Item 1A · See the changes

1. Changes in geopolitical and macroeconomic conditions could negatively affect Abbott’s business, financial condition, and results of operations.new
2. Abbott is subject to cost containment efforts that could cause a reduction in future revenues and operating earnings.reworded
3. Competitors’ intellectual property may prevent Abbott from selling its products or have a material adverse effect on Abbott’s future profitability and financial condition.
4. New products and technological advances by Abbott’s competitors may negatively affect Abbott’s results of operations.
5. Fluctuation in foreign currency exchange rates has adversely affected and may continue to adversely affect Abbott’s financial statements and its ability to realize projected sales and earnings.
6. Adverse changes in tax laws, regulations or interpretations, both in the U.S. and internationally, could have a material adverse effect on Abbott’s effective tax rate, financial condition and results of operations.
7. Deterioration in the economic condition and credit quality of certain countries may negatively affect Abbott’s results of operations.
8. Other factors can have a material adverse effect on Abbott’s future profitability and financial condition.

Read these in Item 1A · See the changes

Headings in the FY2024 10-K with no match this year.

1. Abbott has indebtedness, which could adversely affect its business, including decreasing its business flexibility.
2. Abbott is subject to risks related to public health crises, such as widespread outbreaks of infectious diseases, which could have a material effect on Abbott’s business, financial condition and results of operations.
3. The international nature of Abbott’s business subjects it to additional business risks that may cause its revenue and profitability to decline.